Background: Vaccination constitutes a crucial preventive measure against COVID-19 infection. Concerns have been raised regarding the efficacy of vaccines in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients due to various immunomodulatory medications and potential adverse events that may impact neurological function. This study aimed to explore the implications of COVID-19 vaccination within MS and NMSOD patients and compare it with other neurological disorders (OND).
Method: In this cross-sectional study conducted in Isfahan, Iran, baseline data and information on COVID-19 infections and vaccinations were collected from MS, NMOSD, and OND patients between September 2021 and September 2022. The predominant neurological disorders identified among OND patients encompassed headache, epilepsy, and Parkinson's disease. Logistic regression analysis was employed to compare COVID-19 vaccination outcomes among different patient groups, presenting odds ratios (OR) with 95% confidence intervals (CI).
Results: The study included 1,307 participants, with 738 having MS, 96 having NMOSD, 76 having clinically isolated syndrome (CIS), and 397 having OND. Significantly higher odds of post-vaccination COVID-19 infection were detected in MS (OR = 3.86, p < 0.001) NMOSD (OR = 2.77, p = 0.015) patients than OND patients. The prior history of COVID-19 infection and the type of vaccine administered did not demonstrate significant associations with the likelihood of post-vaccination COVID-19 infection in MS and NMOSD patients (p > 0.05 for all). There were no significant differences in the rates of adverse events in MS, NMOSD, and OND patients, except the second dose, where NMOSD patients had lower odds than OND patients (OR = 0.55, p = 0.019).
Conclusion: Although the safety profile of COVID-19 vaccination in MS and NMOSD was similar to that in OND, the rates of post-vaccination COVID-19 infection in MS and NMOSD seem higher than OND. These findings highlight the importance of regular serological monitoring and the potential advantages of supplementary vaccine doses in MS and NMOSD patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2024.06.028 | DOI Listing |
Risk Manag Healthc Policy
January 2025
School of Public Health, Gudie University Project, Kampala, Uganda.
Aim: This study examined citizens' knowledge and compliance with COVID-19 standard operating procedures (SOPs), vaccine acceptance and hesitancy, and factors that could influence these behaviors.
Methods: The study that utilised the Lot Quality Assurance Sampling (LQAS) approach was conducted in eight districts of Central Uganda; Kiboga, Kyankwanzi, Mubende, Kasanda, Mityana, Luwero, Nakaseke, and Nakasongola districts. Each district was divided into five supervision areas (SAs).
Pak J Med Sci
January 2025
Feyza Koc, MD Associate Professor, Division of Social Pediatrics, Department of Pediatrics, Ege University Children's Hospital, Ege University Faculty of Medicine, Ege University, Bornova, Izmir, Turkey.
Objective: The aim of the study was to examine the effects of the COVID-19 pandemic on frequency of well-child follow-up visits and immunization rate in Turkish tertiary reference hospital's Well-Child Care Outpatient Clinic.
Methods: Children aged one month to 18 years who presented to the Well Child Care Outpatient Clinic of a tertiary referral hospital in Turkey for child health follow-up and immunisation were included in the study. Children with chronic diseases or children who needed to be immunised with a different scheme due to their special conditions were not included.
Popul Res Policy Rev
July 2023
Population Research Institute, Pennsylvania State University, University Park, PA.
Spatially concentrated, vaccine-hesitant populations represent an ongoing challenge to public health policies that emphasize mass vaccination as a means to eradicating certain infectious diseases. Previous research suggests that Amish populations, which are spatially clustered and rapidly growing, may be undervaccinated. However, existing evidence is limited to local case studies in pre-COVID-19 contexts.
View Article and Find Full Text PDFCase Rep Infect Dis
January 2025
Division of Pediatric Infectious Diseases, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
We present the case of a fully vaccinated 39-year-old male with no pertinent past medical history who initially presented with De Quervain's tenosynovitis which was successfully treated with a corticosteroid injection. His symptoms recurred during a COVID-19 infection, which was treated with a repeat corticosteroid injection. Symptoms recurred during an influenza infection and were subsequently treated with a first dorsal compartment release.
View Article and Find Full Text PDFObjectives: Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID-19) as well as impaired responses to COVID-19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was to explore the uptake of the COVID-19 vaccine in this population since records of this are scarce.
Methods: In this nationwide cohort study, we used multiple population-based health and sociodemographic registries to study COVID-19 vaccine uptake in individuals with CLL in Sweden, from 27 December 2020 to 28 February 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!